miércoles, 1 de noviembre de 2023

How Can You Help Patients Prevent Diabetes Complications?

https://www.niddk.nih.gov/health-information/professionals/diabetes-discoveries-practice/how-can-you-help-patients-prevent-diabetes-complications?utm_medium=e-mail&utm_source=diabetes+discoveries+and+practice+blog

Immune boost may protect against multiple hospital-acquired infections

https://www.nih.gov/news-events/nih-research-matters/immune-boost-may-protect-against-multiple-hospital-acquired-infections

Calorie restriction and human muscle function

https://www.nih.gov/news-events/nih-research-matters/calorie-restriction-human-muscle-function

Scientists build largest maps to date of cells in human brain

https://www.nih.gov/news-events/nih-research-matters/scientists-build-largest-maps-date-cells-human-brain

Clinical Trials Update from NCI, October 2023: SBRT Emerging as an Important Treatment for Early-Stage Kidney Cancer

https://content.govdelivery.com/accounts/USNIHNCI/bulletins/378a696?reqfrom=share

FDA Approves Interchangeable Biosimilar for Multiple Inflammatory Diseases

https://www.fda.gov/news-events/press-announcements/fda-approves-interchangeable-biosimilar-multiple-inflammatory-diseases?utm_medium=email&utm_source=govdelivery U.S. Food and Drug Administration approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara (ustekinumab) for multiple inflammatory diseases.